✦ LIBER ✦

Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation

✍ Scribed by Cecilie Blimark; Ljupco Veskovski; Jan Westin; Stig Rödjer; Mats Brune; Martin Hjorth; Erik Holmberg; Per-Ola Andersson; Ulf-Henrik Mellqvist

Book ID: 114795357
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 154 KB
Volume: 87
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2011.01634.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose melphalan (200 mg/m2) supporte

High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (65 years) myeloma patients: comparison with younger patients treated on the same protocol

✍ Jantunen, E; Kuittinen, T; Penttilä, K; Lehtonen, P; Mahlamäki, E; Nousiainen, T 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 135 KB

Triple transplantation of autologous per

Triple transplantation of autologous peripheral blood stem cells each time following conditioning with 100 mg/m2 of melphalan for multiple myeloma patients in poor performance status

✍ M Rokicka; E Urbanowska; T Torosian; J Dwilewicz-Trojaczek; A Awedan; M Paluszew 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Melphalan 200 mg/m2 with blood stem cell

Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival

✍ Carlson, K 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 136 KB

Melphalan 180mg/m2 Can Be Safely Adminis

Melphalan 180mg/m2 Can Be Safely Administered as Conditioning Regimen Prior to an Autologous Stem Cell Transplantation in Multiple Myeloma Patients with Creatinine Clearance ≤60ml/min/1.73 m2 with Use of Palifermin for Cytoprotection: Results of a Phase I Trial

✍ M.H. Abidi; R. Agarwal; N. Tageja; L. Ayash; M. Ventimiglia; A. Deol; Z. Al-Kadh 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 84 KB

A Novel High Dose Chemotherapy Strategy

A Novel High Dose Chemotherapy Strategy With Bendamustine in Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: A Phase I-II Study on 44 Patients

✍ G. Visani; L. Malerba; P.M. Stefani; S. Capria; P. Galieni; F. Gaudio; G. Specch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB